Builds on company's growing position in Canadian sterile
injectables market
LONDON, March 9,
2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC
(Hikma), the multinational pharmaceutical company, announces the
launch of four new sterile injectable medicines in Canada, providing important new treatment
options for patients and health care providers, and building on the
company's growing presence in the Canadian market.
All of the medicines, which will be launched soon, represent the
first or second generic versions of their molecules on the Canadian
market and treat conditions across a variety of therapeutic areas –
a meaningful expansion in access to medicines for Canadian
patients.
The products being launched are:
- Dantrolene Sodium for Injection, USP, 20 mg Vial
- Micafungin Sodium for Injection, 50 mg Vial and 100 mg
Vial
- Mitomycin for Injection, USP, 20 mg Vial
- Progesterone Injection, USP, 50 mg/mL, 10 mL Vial
With these launches, Hikma now markets approximately 30
different sterile injectable medicines in Canada, with plans to launch up to 13
additional sterile injectable products in Canada this year. The company is now a top 10
player in the Canadian generic sterile injectables
market1 and has a leading presence in North America. In the US, Hikma is a top three
supplier by volume of generic injectables to US
hospitals.2
"Since expanding into Canada
last year through the acquisition of Teligent's Canadian injectable
assets, we have been working hard to strengthen relationships with
customers and Health Canada, while setting the stage to introduce
Hikma's leading sterile injectables portfolio into the country,"
said Mike Armstrong, Canada Country
Director, Hikma. "The launch of these new sterile injectable
medicines is a significant step forward in growing our business in
Canada and provides important new
treatment options for patients and health care providers."
"The expansion of our sterile injectable business in
Canada continues the strong
momentum of our Injectables business globally and builds on our
position as a leading supplier of injectable medicines to US
hospitals with a reputation for quality and reliability," said Riad
Mishlawi, President, Injectables, Hikma. "We look forward to
offering Canadian hospitals critical injectable drugs for their
patients' needs and furthering our impact as a growing player in
this important market."
Enquiries
Hikma
Pharmaceuticals PLC
|
Investors:
Susan
Ringdal
EVP, Strategic Planning
and Global Affairs
|
+44 (0)20 7399 2760/
+44 7776 477050
uk-investors@hikma.uk.com
|
|
|
Media:
Steve Weiss
David Belian
US Communications and
Public Affairs
|
+1 732 788
8279
+1 848 254
4875
uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the worled. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and
expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,800
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
These products have been approved for marketing in
Canada by Health
Canada. These product approvals do not confer the right on
Hikma, or any other party, to market these products outside
Canada.
1 IQVIA MAT June
2022, excluding biologics, vaccines, and
EpiPen
2 IQVIA MAT December 2022, generic injectable volumes
by eaches, excluding branded generics and Becton Dickinson
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hikma-expands-impact-in-canada-with-launches-of-new-sterile-injectable-medicines-301767437.html
SOURCE Hikma Pharmaceuticals USA Inc.